The global cell counting market size was estimated at USD 9.48 billion in 2024 and is projected to reach USD 15.46 billion by 2030, growing at a CAGR of 8.7% from 2025 to 2030. As the healthcare sector increasingly moves toward personalized and precision-based therapies, the need for accurate and reliable cell counting techniques has become more essential. These methodologies play a vital role in assessing cell viability, growth, and proliferation, which are foundational parameters in many advanced clinical and research applications.

This shift is especially evident in areas such as stem cell research and the growing field of biologics, where precise cell measurements are required to support the development of targeted treatments for chronic and complex diseases. Improved cell analysis capabilities enhance the ability to monitor disease progression, validate therapeutic responses, and optimize treatment strategies, all of which contribute to the expanding demand for advanced cell counting technologies.

Technological advancements are also reshaping conventional cell counting processes. Automated platforms and high-throughput systems are enabling faster, more accurate, and more consistent analysis, reducing human error and streamlining laboratory workflows. For example, in May 2024, Merck KGaA introduced its M-Trace Electronic Test Record Software, a solution designed to strengthen microbial quality control by digitizing sterility testing. This innovation supports data traceability, minimizes deviations, and enhances compliance and process safety. Likewise, in January 2024, Thermo Fisher Scientific launched the Gibco CTS Cellmation Software, recognized as the first validated platform for automating workflows in cell therapy manufacturing. This software improves integration across instruments, enhances regulatory compliance, and increases operational efficiency, further supporting the market’s evolution.

Key Market Trends & Insights:

• The North America cell counting market continued to lead the global industry, accounting for a 38.2% revenue share in 2024. This strong regional dominance can be attributed to well-established research infrastructure, high adoption of advanced analytical technologies, and significant investments in life science and biotechnology development.

• Within the region, the U.S. cell counting market emerged as the major contributor, holding an impressive 90.8% share of the North America market in 2024. The country’s leadership is supported by a large base of research institutions, expanding biopharmaceutical activities, and the presence of key industry players that consistently invest in R&D and innovation.

• From a product standpoint, the consumables & accessories segment was the leading category, representing 54.0% of the market in 2024. This dominance is driven by the recurring need for reagents, assay kits, cartridges, and other essential laboratory supplies that support routine cell analysis workflows across clinical, research, and industrial laboratories.

• In terms of application, the complete blood count (CBC) segment held the largest share, accounting for 59.2% of the market in 2024. CBC tests remain one of the most widely used diagnostic procedures, supporting disease detection, treatment monitoring, and overall health assessment, thus maintaining consistent demand for reliable cell counting solutions.

• Based on end-use, the research & academic institutes segment led the market with a 39.8% revenue share in 2024. These institutions play a crucial role in driving innovation, conducting cell-based studies, and developing new therapeutic approaches, all of which contribute to the high utilization of cell counting technologies.

Order a free sample PDF of the Cell Counting Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 9.48 Billion

• 2030 Projected Market: USD 15.46 Billion

• CAGR (2025-2030): 8.7%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Some key companies operating in the market include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., and PerkinElmer. The competitive landscape is characterized by strong rivalry among these major players, each focusing on technological innovation and high-quality product development. Significant investment in research and development (R&D) continues to drive advancements in cell counting devices, enabling improved accuracy, automation, and workflow efficiency. This ongoing innovation has also encouraged companies to pursue strategic partnerships, mergers, and acquisitions to expand their product portfolios and strengthen their global presence.

Agilent Technologies, Inc. is known for its specialized expertise in advanced cell counting technologies. The company offers a comprehensive range of innovative instruments and reagents, including flow cytometers and automated cell counters, which are designed to deliver high levels of precision and reproducibility. These solutions support applications in research, diagnostics, and biopharmaceutical development, enabling scientists to achieve better insights into cell behavior, viability, and proliferation. Agilent’s contributions are particularly significant in areas such as personalized medicine and modern drug development, where accurate cell analysis is essential.

BD also plays a prominent role in the market by producing a diverse portfolio of cell counting instruments and consumables. Its offerings include automated hematology analyzers and advanced flow cytometry systems, both of which facilitate reliable and detailed cell counting for clinical and research settings. These technologies contribute to improved disease monitoring, enhanced diagnostic accuracy, and better patient outcomes. Through ongoing innovation and a strong focus on quality, BD continues to support evolving healthcare needs and drive progress in cell analysis methodologies.

Key Players

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Agilent Technologies, Inc.

• PerkinElmer

• BD

• Danaher Corporation

• Bio-Rad Laboratories, Inc.

• GE HealthCare

• DeNovix

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The cell counting market is poised for strong growth driven by rising demand for precision in healthcare, particularly in areas like stem cell research and biologics. Technological advancements—especially in automation and high-throughput systems—are modernizing traditional workflows and improving efficiency. Research institutions remain the primary end users, while the increasing prevalence of chronic diseases fuels the need for accurate cell analysis. Overall, the market’s expansion is underpinned by robust R&D investment and a push toward more tailored therapeutic approaches.